Business
Currency:CNY
2024/H1
Stock NameRevenueRatio
药品销售及特许权使用费收入90.64M52.23%
许可费收入78.2M45.05%
提供用于研发项目的货品╱消耗品收入4.31M2.48%
合作开发及商业化许可费收入416K0.24%
Product
No Data
Region
Currency:CNY
2019/H1
Stock NameRevenueRatio
China9.92M90.00%
Other areas1.1M10.00%